NUPLAZID® (pimavanserin) is a specialized prescription medication developed by Acadia Pharmaceuticals Inc. to address the unique challenges posed by Parkinson’s disease-related hallucinations and delusions, collectively known as Parkinson’s disease psychosis (PDP). Recognizing that approximately 50% of individuals living with Parkinson’s may experience these troubling nonmotor symptoms, NUPLAZID offers hope for those affected.

The medication functions by modulating brain chemicals, including serotonin, without increasing dopamine levels that can exacerbate motor symptoms in Parkinson’s patients. NUPLAZID is specifically indicated for the treatment of hallucinations and delusions associated with this condition, helping patients regain a sense of reality.

In addition to providing vital medication, Acadia Pharmaceuticals supports patients and their caregivers with resources to better understand and manage the psychological dimensions of Parkinson’s disease. The brand emphasizes the importance of open communication with healthcare providers and offers a wealth of information on the nature of Parkinson’s disease, its symptoms, and personal stories that illustrate the journey of those living with PDP.